T1	PrimaryOutcome 270 295	elimination of SARS-CoV-2
T2	TimeFrame 296 305	by Day 10
T3	OutcomeDefinition 307 373	defined as two negative PCR tests with at least a 24-hour interval
R1	MeasuredAt Arg1:T1 Arg2:T2	
R2	DefinedAs Arg1:T1 Arg2:T3	
T4	OtherOutcome 551 568	daily vital signs
T5	OtherOutcome 570 632	SpO2 and WHO Ordinal Scale for Clinical Improvement (WHO-OSCI)
T6	OtherOutcome 634 662	PCR for SARS-CoV-2 detection
T7	TimeFrame 724 745	on Days 5, 10, and 15
R3	MeasuredAt Arg1:T6 Arg2:T7	
T8	OtherOutcome 747 782	chest computed tomography (CT) scan
T9	TimeFrame 783 808	at baseline and on Day 15
R4	MeasuredAt Arg1:T8 Arg2:T9	
T10	OtherOutcome 810 830	physical examination
T11	OtherOutcome 832 852	complete blood count
T12	OtherOutcome 854 866	biochemistry
T13	OtherOutcome 868 892	C-reactive protein (CRP)
T14	OtherOutcome 894 904	urinalysis
T15	OtherOutcome 910 927	electrocardiogram
T16	TimeFrame 928 960	at baseline and on Days 5 and 15
R5	MeasuredAt Arg1:T15 Arg2:T16	
T17	SecondaryOutcome 1574 1597	rate of viral clearance
T18	TimeFrame 1598 1606	by Day 5
R6	MeasuredAt Arg1:T17 Arg2:T18	
T19	SecondaryOutcome 1608 1673	time to normalization of clinical symptoms (ie, body temperature)
T20	SecondaryOutcome 1675 1693	changes on CT scan
T21	TimeFrame 1694 1703	by Day 15
R7	MeasuredAt Arg1:T20 Arg2:T21	
T22	SecondaryOutcome 1709 1775	incidence and severity of adverse events related to the study drug
